S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000821452.65842.6a |